Key result
Calcium channel antagonists such as verapamil and diltiazem are safe and effective in effort angina and post-infarct follow-up, provided clinical heart failure is excluded.
Why the study?
Are calcium channel antagonists safe and effective in protecting patients with coronary artery disease?
Are calcium channel antagonists safe and effective in protecting patients with coronary artery disease?
Answers are grounded in this paper and cite their sources.
This review supports the safety and efficacy of non-dihydropyridine calcium channel blockers like verapamil in specific coronary artery disease settings, provided heart failure is excluded.
Calcium antagonists have multiple mechanisms whereby they are able to protect against myocardial ischaemia. Recently questions have been posed about the long-term safety of this group of agents. This article is a selective rather than a complete review of the problems. Fears have largely centred around rapidly acting nifedipine when inappropriately used. This agent remains useful in Prinzmetal's angina, a condition in which there are no long-term comparative outcome studies. Current evidence is that verapamil is as safe and as effective as the beta-blocker in effort angina and that non-dihydropyridines (verapamil and diltiazem) are efficacious in the follow up of non-Q wave infarct. Verapamil post-infarct is safe and reduces reinfarction, provided that clinical heart failure is first excluded.
No takes yet. Share an insight, caveat, or question.
Lionel H. Opie (1997) conducted a review in Coronary artery disease. Calcium channel antagonists was evaluated. Calcium channel antagonists such as verapamil and diltiazem are safe and effective in effort angina and post-infarct follow-up, provided clinical heart failure is excluded.
Synapse has enriched 10 related papers. Consider them for comparative context: